Managing thalassemia in the developing world: an evidence-based approach for prevention, transfusion independency, and curative treatment with hematopoietic stem cell transplantation.
作者信息
Ansari Saqib Hussain, Parveen Sadia, Siddiqui Saima, Perveen Kousar, Ahmed Ghazala, Kaleem Bushra, Ahmed Shariq, Zohaib Muhammad, Farzana Tasneem, Shamsi Tahir
机构信息
National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan.
出版信息
Blood Adv. 2018 Nov 30;2(Suppl 1):42-45. doi: 10.1182/bloodadvances.2018GS112057.
Abstract
摘要
相似文献
1
Managing thalassemia in the developing world: an evidence-based approach for prevention, transfusion independency, and curative treatment with hematopoietic stem cell transplantation.发展中世界的地中海贫血管理：一种基于证据的预防、摆脱输血及造血干细胞移植治愈性治疗方法。
Blood Adv. 2018 Nov 30;2(Suppl 1):42-45. doi: 10.1182/bloodadvances.2018GS112057.
2
Thalassemia.地中海贫血
Pediatr Rev. 2012 Sep;33(9):434-5; discussion 435. doi: 10.1542/pir.33-9-434.
3
Thalassemia: the continued challenge.地中海贫血：持续的挑战。
Ann N Y Acad Sci. 2005;1054:1-10. doi: 10.1196/annals.1345.001.
4
Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.非输血依赖型地中海贫血和中间型地中海贫血：流行病学、并发症及管理
Curr Med Res Opin. 2016;32(1):191-204. doi: 10.1185/03007995.2015.1110128. Epub 2015 Nov 25.
5
New updating into hemoglobinopathies.血红蛋白病的新进展。
Int J Lab Hematol. 2012 Dec;34(6):559-65. doi: 10.1111/j.1751-553X.2012.01446.x. Epub 2012 Jul 5.
6
Beta-thalassemia.β地中海贫血
N Engl J Med. 2005 Sep 15;353(11):1135-46. doi: 10.1056/NEJMra050436.
7
Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong province.中国地中海贫血的发病率及治疗情况，特别提及深圳市和广东省
Hemoglobin. 2009;33(5):296-303. doi: 10.3109/03630260903211698.
8
Is there a standard-of-care for transfusion therapy in thalassemia?地中海贫血输血治疗有护理标准吗？
Curr Opin Hematol. 2017 Nov;24(6):558-564. doi: 10.1097/MOH.0000000000000373.
9
Thalassemia in Thailand.泰国的地中海贫血症。
Hemoglobin. 2022 Jan;46(1):53-57. doi: 10.1080/03630269.2022.2025824.
10
Sickle cell anaemia: current therapies.镰状细胞贫血：当前的治疗方法。
Transfus Apher Sci. 2013 Oct;49(2):151-4. doi: 10.1016/j.transci.2013.07.018. Epub 2013 Aug 15.
引用本文的文献
1
Prenatal diagnosis of thalassemia in 695 pedigrees from southeastern China: a 10-year follow-up study.中国东南部 695 个家系的地中海贫血症产前诊断：一项为期 10 年的随访研究。
J Clin Lab Anal. 2021 Oct;35(10):e23982. doi: 10.1002/jcla.23982. Epub 2021 Sep 4.
2
Discovery of Novel Fetal Hemoglobin Inducers through Small Chemical Library Screening.通过小型化学文库筛选发现新型胎儿血红蛋白诱导剂。
Int J Mol Sci. 2020 Oct 8;21(19):7426. doi: 10.3390/ijms21197426.
3
Prevalence of Transfusion Transmissible Infections in Beta-Thalassemia Major Patients in Pakistan: A Systematic Review.巴基斯坦重型β地中海贫血患者输血传播感染的患病率：一项系统评价
Cureus. 2020 Aug 27;12(8):e10070. doi: 10.7759/cureus.10070.
4
[Research advances in transplantation for thalassemia major].[重型地中海贫血移植治疗的研究进展]
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Jan;22(1):77-81. doi: 10.7499/j.issn.1008-8830.2020.01.015.
本文引用的文献
1
Pharmacoproteomics Profiling of Plasma From β-Thalassemia Patients in Response to Hydroxyurea Treatment.羟脲治疗β-地中海贫血患者血浆的药物蛋白质组学分析。
J Clin Pharmacol. 2019 Jan;59(1):98-106. doi: 10.1002/jcph.1297. Epub 2018 Aug 27.
2
β-Thalassemia Patients Revealed a Significant Change of Untargeted Metabolites in Comparison to Healthy Individuals.与健康个体相比，β-地中海贫血患者的非靶向代谢物发生了显著变化。
Sci Rep. 2017 Feb 13;7:42249. doi: 10.1038/srep42249.
3
Molecular epidemiology of β-thalassemia in Pakistan: far reaching implications.巴基斯坦β地中海贫血的分子流行病学：影响深远
Int J Mol Epidemiol Genet. 2011;2(4):403-8. Epub 2011 Nov 28.
4
Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.羟基脲在β地中海贫血中实现输血独立的疗效。
J Pediatr Hematol Oncol. 2011 Jul;33(5):339-43. doi: 10.1097/MPH.0b013e31821b0770.
5
Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).羟基脲（HU）对减少重型β地中海贫血患儿红细胞（PRC）输注需求的疗效：卡拉奇羟基脲试验（KHUT）。
J Pediatr Hematol Oncol. 2007 Nov;29(11):743-6. doi: 10.1097/MPH.0b013e318157fd75.
Zotero 插件